Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • Vardenafil HCl Trihydrate: Potent PDE5 Inhibitor for Prot...

    2026-03-11

    Vardenafil HCl Trihydrate: Potent PDE5 Inhibitor for Proteoform-Resolved cGMP Signaling

    Executive Summary: Vardenafil HCl Trihydrate is a potent, selective phosphodiesterase type 5 (PDE5) inhibitor with an in vitro IC50 of 0.7 nM, demonstrating high selectivity over other PDE isoforms (APExBIO, product page). It acts by increasing cGMP levels and promoting vascular smooth muscle relaxation (Lutomski et al., 2025, DOI). Proteoform-specific binding profiles have been resolved using native mass spectrometry, revealing minimal off-target effects on PDE6 under physiological conditions (ibid). The compound is highly soluble in water (≥95 mg/mL) and stable at -20°C as a solid. Vardenafil HCl Trihydrate is a critical research tool for precision studies in cGMP signaling, erectile dysfunction models, and smooth muscle physiology (related article).

    Biological Rationale

    Phosphodiesterase type 5 (PDE5) regulates cyclic guanosine monophosphate (cGMP) signaling in vascular smooth muscle. cGMP mediates vasodilation and smooth muscle relaxation, playing a pivotal role in erectile function and vascular homeostasis (Lutomski et al., 2025). Dysregulation of PDE5 activity is implicated in erectile dysfunction and certain cardiovascular pathologies. Selective PDE5 inhibitors, such as Vardenafil HCl Trihydrate, enable direct interrogation of cGMP-dependent signaling pathways in both in vitro and in vivo models. Proteoform diversity and post-translational modifications (PTMs) of PDE5 and related signaling proteins modulate drug response and tissue specificity (DOI). Recent advances in mass spectrometry-based proteomics have allowed researchers to resolve these proteoform-specific effects and off-target interactions at unprecedented resolution (see related discussion—this article extends proteoform-level insights with updated benchmark data).

    Mechanism of Action of Vardenafil HCl Trihydrate

    Vardenafil HCl Trihydrate (APExBIO, A4323) is a competitive inhibitor of PDE5. It binds to the catalytic domain of PDE5, preventing the hydrolysis of cGMP to 5'-GMP. This leads to increased intracellular cGMP concentrations, which activate protein kinase G (PKG), resulting in smooth muscle relaxation and vasodilation. In human trabecular smooth muscle assays, Vardenafil HCl Trihydrate exhibits an IC50 of 0.7 nM for PDE5, with significantly higher IC50 values for PDE1, PDE2, PDE3, PDE4, and PDE6, indicating high isoform selectivity (APExBIO). Off-target binding to PDE6, a retinal isoform, has been observed at supratherapeutic concentrations, but is minimal under physiological conditions (Lutomski et al., 2025). This selectivity is crucial for minimizing vision-related side effects. The compound's action has been confirmed in conscious rabbit models, demonstrating dose-dependent enhancement of erectile responses (prior article—here we clarify the role of selectivity in translational settings).

    Evidence & Benchmarks

    • Vardenafil HCl Trihydrate inhibits human PDE5 with an IC50 of 0.7 nM in enzymatic assays at 25°C, pH 7.4 (APExBIO, product page).
    • Mass spectrometry-based proteomics reveals differential binding of Vardenafil and other PDE5 inhibitors to PDE6 proteoforms, with Vardenafil showing lower off-target affinity in native membrane environments (Lutomski et al., 2025).
    • In conscious rabbit models, Vardenafil HCl Trihydrate potentiates erectile response in a dose-dependent manner (2–20 µg/kg, intravenous) with measurable increases in corpus cavernosum pressure (see APExBIO technical data).
    • The compound is highly soluble in water (≥95 mg/mL), DMSO (≥13.3 mg/mL), and ethanol (≥3.42 mg/mL with warming/ultrasonication), enabling broad assay compatibility (APExBIO).
    • Proteoform-specific PDE5 inhibition can be directly measured using native mass spectrometry workflows, expanding the scope of cGMP signaling research (DOI).

    Applications, Limits & Misconceptions

    Vardenafil HCl Trihydrate is a preferred tool for:

    • PDE5 inhibition assays in biochemical, cellular, and tissue models.
    • Research on cGMP signaling pathway dynamics in vascular and erectile dysfunction models.
    • Studies requiring proteoform-selective pharmacology, leveraging native mass spectrometry (related article—this page updates practical advice for next-generation proteomics workflows).
    • Smooth muscle relaxation research in human and animal systems.

    Common Pitfalls or Misconceptions

    • Vardenafil HCl Trihydrate is not suitable for long-term solution storage; use freshly prepared solutions to ensure potency (store solid at -20°C).
    • It is not a pan-phosphodiesterase inhibitor; activity is highly selective for PDE5 and does not generalize to all PDE isoforms.
    • PDE6 inhibition can occur only at high (non-physiological) concentrations, thus vision-related off-target effects are rare in research settings (DOI).
    • Not indicated for direct clinical or diagnostic use; for research purposes only (APExBIO).
    • Batch-to-batch assay conditions (e.g., buffer, temperature, species) can influence observed potency and selectivity; always standardize protocols.

    Workflow Integration & Parameters

    To maximize reproducibility and data quality:

    • Dissolve Vardenafil HCl Trihydrate in water, DMSO, or ethanol per required assay, ensuring concentrations ≥10x IC50 for stock solutions.
    • For enzymatic assays, maintain assay temperature at 25°C and buffer at pH 7.4 unless otherwise specified.
    • For mass spectrometry-based proteomics, ensure compatibility with native or denaturing LC–MS/MS protocols. Avoid prolonged exposure to aqueous solutions before analysis.
    • Store solid compound at -20°C in airtight containers; avoid freeze-thaw cycles.
    • Consult APExBIO technical documentation for compound-specific handling, solubility, and stability data (APExBIO product page).

    Conclusion & Outlook

    Vardenafil HCl Trihydrate (APExBIO, A4323) is a gold-standard, potent, and selective tool for probing cGMP signaling and vascular smooth muscle relaxation. Its nanomolar potency, high water solubility, and minimal off-target profile facilitate robust, proteoform-resolved research in both classic and emerging workflows. Recent advances in native mass spectrometry and proteomics now enable direct measurement of PDE5–ligand interactions within their native membrane context, improving translational relevance and drug safety (Lutomski et al., 2025). This article extends prior best practices and benchmark data (see strategic guidance—here, we focus on the mechanistic and workflow boundaries for advanced users). As proteoform-specific pharmacology matures, Vardenafil HCl Trihydrate will remain essential for next-generation studies in PDE5 inhibition, vascular biology, and translational medicine.